000099192 001__ 99192
000099192 005__ 20210902121938.0
000099192 0247_ $$2doi$$a10.31083/J.EJGO.2020.06.2191
000099192 0248_ $$2sideral$$a122690
000099192 037__ $$aART-2020-122690
000099192 041__ $$aeng
000099192 100__ $$aBaquedano Mainar, L.$$uUniversidad de Zaragoza
000099192 245__ $$aHE4 in endometriod and non- Endometrioid subtype of endometrial cancer does not mean the same
000099192 260__ $$c2020
000099192 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099192 5203_ $$aObjective: To study the association between the preoperative value of serum HE4 marker and poor histological prognostic factors depending on the subtype of endometrial cancer (EC): endometrioid and non-endometrioid tumors.
Methods: Prospective and multicenter cohort study including patients with EC in Miguel Servet University Hospital of Zaragoza (Spain) and Hospital Clínico San Carlos of Madrid (Spain) from January 2017 to March 2020. Preoperative serum levels of HE4 were analyzed by clinical and pathological characteristics.
Results: Overall, 190 patients were included. Of them, 158 were subtype I of EC and 32 were subtype II tumors. In endometrioid EC, a statistically significant association was found between the preoperative HE4 value and tumor size (p < 0.001), deep myometrial invasion (p = 0.001), lymphovascular space invasion (LVSI) (p = 0.002), cervical (p = 0.001), adnexal (p = 0.023), isthmus (p < 0.001) and parametrial involvement (p = 0.012), lymph node metastasis (p = 0.025) and FIGO stage (p < 0.001). On the contrary, no histological factors showed statistical association except LVSI (p = 0.025) in the non-endometrioid subtype.
Conclusions: The preoperative value of HE4 is related differently with several established prognostic factors for EC according to the histological type of tumor. These results could be relevant in order to standardize a prognostic value of HE4 in EC.
000099192 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099192 590__ $$a0.196$$b2020
000099192 591__ $$aONCOLOGY$$b240 / 242 = 0.992$$c2020$$dQ4$$eT3
000099192 591__ $$aOBSTETRICS & GYNECOLOGY$$b81 / 83 = 0.976$$c2020$$dQ4$$eT3
000099192 592__ $$a0.15$$b2020
000099192 593__ $$aOncology$$c2020$$dQ4
000099192 593__ $$aObstetrics and Gynecology$$c2020$$dQ4
000099192 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099192 700__ $$aEspiau Romera, A..
000099192 700__ $$aCoronado Martín, P.J.
000099192 7102_ $$11013$$2645$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Obstetricia y Ginecología
000099192 773__ $$g41, 6 (2020), 1039-1044$$pEur. j. gynaecol. oncol.$$tEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY$$x0392-2936
000099192 8564_ $$s157457$$uhttps://zaguan.unizar.es/record/99192/files/texto_completo.pdf$$yVersión publicada
000099192 8564_ $$s2916495$$uhttps://zaguan.unizar.es/record/99192/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099192 909CO $$ooai:zaguan.unizar.es:99192$$particulos$$pdriver
000099192 951__ $$a2021-09-02-10:59:44
000099192 980__ $$aARTICLE